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Background: Infection occurs commonly among patients hospitalized after traumatic brain injury (TBI) and has
been associated with increased intensive care unit and hospital lengths of stay and an elevated risk of poor
neurological outcome and mortality. However, as many relevant published studies to date have varied in the type
and severity of TBI among included patients as well as in their design (randomized versus non-randomized), risk of
bias, and setting (hospital ward versus intensive care unit), their reported estimates of infection occurrence vary
considerably. Thus, the purpose of this systematic review and meta-analysis is to estimate the incidence, prevalence,
and occurrence rate of infection among patients hospitalized after TBI.
Methods/Design: We will search electronic bibliographic databases (MEDLINE, EMBASE, PubMed, Cumulative Index
to Nursing and Allied Health Literature (CINAHL), Scopus, Web of Science, the Cochrane Central Register of
Controlled Trials (CENTRAL), and the Cochrane Database of Systematic Reviews) from their first available date as
well as personal files, reference lists of included articles, and conference proceedings. Two investigators will
independently screen titles and abstracts and select cohort studies, cross-sectional studies, and randomized controlled
trials involving adults hospitalized after TBI that reported estimates of cumulative incidence, incidence rate, prevalence,
or occurrence rate of infection for inclusion in the systematic review. These investigators will also independently extract
data and assess risk of bias. We will exclude studies with fewer than ten patients; experimental groups allocated to
treatment with antibiotics, glucocorticoids, immunosuppressants, barbiturates, or hypothermia; and studies focused on
military/combat-related TBI. Pooled estimates of cumulative incidence, incidence rate, prevalence, and occurrence rate
will be calculated using random effects models. We will also calculate I2 and Cochran Q statistics to assess for
inter-study heterogeneity and conduct stratified analyses and univariate meta-regression to determine the
influence of pre-defined study-level covariates on our pooled estimates.
Discussion: This study will compile the world literature regarding the epidemiology of infection among adults
hospitalized after TBI. A better understanding of the role of infection will be helpful in the development of
guidelines for patient management. This protocol has been registered in the PROSPERO International Prospective
Register of Systematic Reviews (ID: CRD42013005146).
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Infection is common among hospitalized patients and
associated with substantially increased health care costs
and worsened outcomes. Nosocomial infections affect
approximately 2 million patients in the United States
each year, increasing overall patient care costs by an
estimated $4.5 to $5.7 billion [1,2]. Patients who de-
velop an infection while in hospital are more likely to
have longer hospital stays and adverse outcomes than
those who do not [3-7]. Moreover, the development
of a severe infection or sepsis has been associated
with an increased risk of physical disability, perman-
ent organ damage, cognitive impairment, and death
[3,8,9].
Approximately 5% to 10% of patients admitted to an
acute care hospital, and 9% to 37% of those admitted to
an intensive care unit (ICU), will acquire one or more
infections [1,10]. Patients with neurological injury, such
as stroke and traumatic brain injury (TBI), appear to be
particularly susceptible to infection [6,7,11-14]. Although
aspiration due to a decreased level of consciousness may
explain the development of pneumonia among some
patients, research also suggests that catecholamines re-
leased as a result of brain injury-induced sympathetic
activation may modulate cells of the immune system
and induce systemic immunosuppression [15-20]. While
this immune suppression may protect the brain from
further inflammatory damage, it may also increase sus-
ceptibility to infection among those with acquired brain
injury [16,17,19].
Among patients with stroke, a systematic review and
meta-analysis reported that the pooled incidence of
infection was 30%, with pneumonia and urinary tract
infections being most common [7]. This study also reported
that the incidence of infection for patients admitted to the
ICU after stroke was significantly higher (45% versus 28%)
[7]. In comparison to stroke, patients withTBI have an even
higher reported incidence of infection. It is estimated that
approximately 50% of patients with severe TBI develop at
least one infectious complication during hospitalization
[12-14,21]. Among those who develop infection, the most
frequent location is the lung, with reported incidences
of pneumonia ranging between 41% and 74% [12-14,21].
Moreover, sepsis has been found to affect between
10% and 41% of patients with severe TBI during
hospitalization [6,13].
As patients with severe TBI (Glasgow Coma Score ≤8)
have a significantly higher incidence of infection and
sepsis compared to patients with mild or moderate TBI
(Glasgow Coma Score >8), the risk of infection may
correlate with severity of brain injury [6,11,12]. Among
ICU patients, reported risk factors for infection in-
clude mechanical ventilation, presence of indwelling
invasive devices, administration of immunosuppressivedrugs, long-term or repeated use of antibiotics, and de-
creased host defenses due to poor chronic health status
and/or acute disease processes [10]. It was found that
patients with TBI who spent more than 7 days in an
ICU had an increased risk for infection as compared to
those who were not admitted or spent ≤7 days in an
ICU [5].
To date, there has been no formal attempt to systemat-
ically review the published literature describing the epi-
demiology of infection after TBI. Therefore, it remains
unknown whether the high reported estimates of infection
in this population are homogenous across the literature.
Moreover, many of the relevant published studies to
date have varied in the type and severity of TBI among
included patients as well as in their design (randomized
versus non-randomized), risk of bias, and setting (hospital
ward versus ICU). Thus, their reported results vary con-
siderably. Therefore, the purpose of this systematic review
and meta-analysis is to estimate the cumulative incidence,
incidence rate, point prevalence, and occurrence rate
of overall infection, as well as pneumonia (community-
acquired, hospital-acquired, ventilator-associated), urinary
tract infection, central nervous system infection, blood-
stream infection, sepsis, severe sepsis, and septic shock
among patients hospitalized after TBI. We also aim to
synthesize and compare the incidence, prevalence, and
occurrence rate of infection observed across random-
ized versus non-randomized studies. We will identify
study and population characteristics associated with
infection, define risk groups based on TBI severity
(mild, moderate, severe), and identify sources of het-
erogeneity across these studies. A better understanding
of the risk of infection among patients with TBI could
assist healthcare providers in identifying patient sub-
groups that may benefit from preventative or early
treatment efforts and may provide evidence to support
priority setting for the allocation of scarce healthcare
resources and research funds.Methods/Design
Protocol and study overview
Methods for this systematic review and meta-analysis
have been developed according to recommendations
from the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses [22] and the Meta-Analysis
of Observational Studies in Epidemiology [23] statements.
We will begin by developing a comprehensive database
containing all published estimates of the cumulative
incidence, incidence rate, prevalence, and occurrence
rate of infection among adults hospitalized after TBI.
The goal of this database will be to comprehensively
and critically analyze the world’s relevant literature in
order to better understand the epidemiology of infection
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The population of interest will include adult (≥16
years old) civilian patients hospitalized after TBI. TBI
will be defined as “an alteration in brain function, or
other evidence of brain pathology, caused by an exter-
nal force” [24]. Whenever available, the comparison
group will include adult (≥16 years old) hospitalized
patients without TBI.
Outcome
The outcome will be the cumulative incidence (also
known as incidence proportion), incidence rate, point
prevalence (herein referred to as prevalence), and occur-
rence rate of overall infection, pneumonia (community-
acquired, hospital-acquired, ventilator-associated), urinary
tract infection, central nervous system infection, blood-
stream infection, sepsis, severe sepsis, and septic shock
(see below for methods detailing how these measures will
be calculated). Although the definitions afforded by the
Centers for Disease Control and Prevention Standardized
Criteria [25] will be used whenever possible to define the
above listed types of infections, we will accept alternate
definitions used by authors (and these will be recorded
and reported).
Study design
Cohort studies, cross-sectional studies, and randomized
controlled trials (RCTs) will be included.
Search strategy
The preliminary search strategy was developed by
three investigators (BNVS, DJR, and DAZ) and will be
subsequently refined by a librarian-scientist (HLR) by
conducting iterative database queries and incorporat-
ing novel search terms once new and relevant articles
are identified. We will search the following electronic
bibliographic databases from their first available date
without restrictions: Ovid MEDLINE, Ovid EMBASE,
PubMed, Cumulative Index to Nursing and Allied
Health Literature (CINAHL), Scopus, Web of Science,
the Cochrane Central Register of Controlled Trials
(CENTRAL), and the Cochrane Database of System-
atic Reviews. The search will cover the themes TBI,
infection, and incidence/prevalence. For the MEDLINE
and EMBASE searches, filters for each search theme
will be constructed using a combination of exploded
Medical Subject Heading (MeSH)/Emtree terms and
text words, each combined through use of the Booleanoperator ‘OR’. The search themes will subsequently
be combined using the Boolean operator ‘AND’ (see
Appendix 1 in Additional File 1 for the final proposed
MEDLINE search strategy and Appendix 2 in Additional
File 2 for the final proposed EMBASE search strategy).
Similar searches will subsequently be conducted in
the remaining databases. Additional citations will be
located by searching conference proceedings (The American
Association of Neurological Surgeons, Neurocritical
Care Society, Society of Critical Care Medicine, The
American Association for the Surgery of Trauma, The
Trauma Association of Canada, The Eastern Association
for the Surgery of Trauma, and The Western Trauma
Association), personal files, and reference lists of rele-
vant reviews and included articles.Study selection
Two investigators (BNVS and DJR) will independently
screen titles and abstracts to identify studies concerning
infection among adult civilian patients hospitalized after
TBI. Articles will be included if they meet the following
criteria: 1) original research; 2) cohort, cross-sectional,
or RCT study design; and 3) reported a cumulative inci-
dence, incidence rate, prevalence, or occurrence rate
of infection (or sufficient information is available to
calculate an estimate). We will exclude: 1) animal stud-
ies; 2) pediatric studies; 3) case reports, case-series,
case-control studies, and non-original articles; 4) studies
that included fewer than ten patients; 5) treatment groups
in studies investigating the effect of prophylactic anti-
biotics, glucocorticoids, immunosuppressants, barbitu-
rates, or hypothermia; and 6) studies focused on military/
combat-related TBI, as the results would not be general-
izable to the source population of civilian patients with
TBI. Studies that report composite outcomes (for ex-
ample, rate of infection and mortality), without sufficient
information to obtain an individual estimate of infection
will be excluded. Among RCTs that meet the inclusion
criteria, we will include only the placebo group (and
not the treatment group) for studies examining the
interventions listed above (prophylactic antibiotics,
glucocorticoids, immunosuppressants, barbiturates, and
hypothermia) as these treatments are known to influence
the risk of infection. In contrast, we will include both
the placebo and treatment groups for RCTs that meet
the inclusion criteria in which the intervention is not
one listed above (for example, trials examining use of
calcium channel blockers or anti-epileptic drugs). A
kappa (κ) statistic will be calculated to quantify the
extent of inter-observer agreement on independent
inclusion of articles [26]. Inclusion disagreement will
be discussed and resolved by consensus or arbitration
by a third investigator (DAZ).
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The same two investigators (BNVS and DJR) will in-
dependently extract data from eligible studies using a
pre-designed and pilot tested electronic data extrac-
tion form. We will extract data on:
1) Publication details: year and language of
publication and country in which the study was
conducted.
2) Design: type of study (cohort, cross-sectional,
RCT); study temporality (prospective,
retrospective); patient enrollment (consecutive,
non-consecutive); hospital setting (ICU, ward);
use of Centers for Disease Control and
Prevention standardized criteria [25] (yes, no, or
unknown); and additional data for quality
assessment (see below). Study design will be
classified using the scheme developed by
Oleckno [27]. Cohort studies and case series will
be differentiated using the recommendations by
Dekkers and colleagues [28].
3) Study participant details: patient characteristics
(age, sex, median Glasgow Coma Score); number
of patients enrolled in the study; number of
patients with TBI; description of patients with
TBI (isolated TBI or poly-trauma; blunt TBI or
penetrating TBI; mild TBI (Glasgow Coma
Score ≥13), moderate TBI (Glasgow Coma Score
of 9 to 12), severe TBI (Glasgow Coma Score ≤8),
or mixed severity of TBI); number of control
patients; description of control patients
(neurological or non-neurological; hospital
controls, ICU controls, healthy controls, or other
(if other, description of control group will be
recorded)); Injury Severity Score of patients
(number with major trauma (Injury Severity
Score >15), number with minor trauma (Injury
Severity Score ≤15); or the study’s mean/median
Injury Severity Score is >15 versus ≤15); the
percentage of patients who received mechanical
ventilation; and the percentage of patients who
received β-adrenergic receptor agonists and
β-adrenergic receptor antagonists, as animal [20]
and human [29] studies have suggested that
treatment with β-adrenergic receptor
antagonists after stroke is associated with
reduced infection.
4) Data for outcome measures: All reported
estimates, or sufficient information to calculate an
estimate, of cumulative incidence, incidence rate,
prevalence, and occurrence rate of infection
(overall infection), pneumonia (community-
acquired, hospital-acquired, or ventilator-
associated), urinary tract infection, centralnervous system infection, bloodstream infection,
sepsis, severe sepsis, and septic shock among
adult patients hospitalized with TBI and, if
available, without TBI (control patients) in
included articles will be extracted. Where
available, we will also extract odds ratios or
relative risks adjusted for potential confounding
factors relating the differential odds or risk of
infection among patients with TBI versus those
without TBI.Quality assessment
The same two reviewers (BNVS and DJR) will also in-
dependently evaluate risk of bias among the included
studies. The quality of observational studies will be
assessed using the framework described by Hayden et al.,
which evaluates study participation, study attrition,
outcome measurement, and statistical analyses among
prognostic studies included in systematic reviews using
a simple ‘yes’, ‘partly’, ‘no’, ‘unsure’ scale [30]. As the
commonly used Jadad score and Cochrane Collabor-
ation criteria (which largely consider the adequacy of
randomization, allocation concealment, withdrawals
and dropouts, and other features) [31,32] are likely less
relevant for the assessment of prognosis studies, the
same tool will also be used to assess the quality of
RCTs (with the exception of the statistical analyses cat-
egory). We will also describe the following characteris-
tics for each study included in our analysis: study
temporality (prospective, retrospective); patient enroll-
ment (consecutive, non-consecutive); the percentage
of patients who received mechanical ventilation; and
whether the study used Centers for Disease Control
and Prevention standardized criteria for infection classi-
fication [25].Data synthesis
Both a narrative synthesis and, where possible, a quanti-
tative meta-analysis of the data will be presented. Studies
will be clustered according to design (randomized versus
non-randomized), setting (ICU versus non-ICU), sever-
ity of TBI, and, where available, timing of determination
of occurrence rate estimates. After the studies have been
grouped into common clusters, their characteristics
(including their specific design and study details and a
description of the number and characteristics of the study
participants included) will be presented in summary tables
[33]. These study groupings will also be utilized to identify
those studies for which occurrence rate estimates have
been derived from similar enough patient populations and
study designs such that a quantitative meta-analysis may
be possible.
Scott et al. Systematic Reviews 2013, 2:68 Page 5 of 7
http://www.systematicreviewsjournal.com/content/2/1/68Statistical analyses
Calculation of individual study estimates of cumulative
incidence, incidence rate, prevalence, and occurrence
rate of infection among patients hospitalized after TBI
We will begin by calculating the cumulative incidence,
incidence rate, prevalence, and occurrence rate of infec-
tion among patients with (or, when available, without)
TBI as reported by observational studies and RCTs. Cu-




Number of new cases of infection
during hospitalization or ICU stay
Total population at risk
where the total population at risk will be defined as the
number of adult hospitalized patients with TBI who do
not have infection at the time of hospital or ICU admis-
sion in order to capture only those cases that are en-




Number of new cases of infection
during hospitalization or ICU stay
Total person‐time at risk
where person-time will be defined as the length of hos-
pital or ICU stay in days among adult patients with TBI.
Prevalence will be defined as:
Prevalence
¼
Number of existing cases of infection
at a specific point in time
during hospitalization or ICU stay
Total defined population
at the same point in time
where the defined population will be adult hospitalized
patients with TBI. As it is often difficult to distinguish
between truly incident versus prevalent cases, we will
also estimate the occurrence rate [34] of infection,
which will be calculated using the formula:
Occurrence rate
¼
Number of cases of infection
during hospitalization or ICU stay
Total number of patients
examined=enrolled in the study
where the patients examined/enrolled in the study will
be adult hospitalized patients with TBI.
The standard error and 95% confidence interval of
these proportions will then be determined using the
Clopper-Pearson exact binomial method [35].Calculation of pooled estimates of cumulative incidence,
incidence rate, prevalence, and occurrence rate of infection
among patients hospitalized after TBI
Individual incidence, prevalence, and occurrence rate es-
timates from observational studies and RCTs will then
be pooled separately using a random effects model
according to the method developed by DerSimonian and
Laird [36]. Importantly, a random effects model was
chosen as variability in measures of occurrence beyond
chance is expected across studies. The pooled estimates
obtained from these calculations will then be com-
pared qualitatively to determine if experimental versus
observational study design is associated with a differ-
ent overall estimate of pooled incidence, prevalence,
or occurrence rate of infection among those with TBI.
We will also perform a cumulative meta-analysis, in
which the estimates of infection over each year will be
determined separately for RCTs and observational
studies in order to determine the impact of each
added study on the pooled estimates of infection over
time.
Calculation of the pooled differential odds of infection
among patients with TBI versus those without TBI
Where available, estimates of the most-adjusted preva-
lence or incidence odds ratio relating the odds of infec-
tion among patients with TBI versus those without TBI
will be pooled using random effects models and the
methods previously outlined by Ronksley and colleagues
for handling variably adjusted individual study estimates
[37]. Individual odds ratio estimates will only be entered
into the model when the odds ratio was estimated from
similar study designs and patient populations (for ex-
ample, cohort studies relating the odds of infection
among poly-trauma patients with TBI versus without
TBI). If only relative risks are available from any of the
identified studies, these measures will be converted into
odds ratios using the method proposed by Deeks and
Altman [38].
Influence and outlier analyses and examination for
evidence of heterogeneity or small study effects potentially
due to publication bias
We will examine heterogeneity separately in the pooled
estimates obtained from randomized and observational
studies using the Cochran Q (P value <0.05 considered
significant) and I2 (a value greater than 50% representing
at least moderate heterogeneity) statistics [31]. In the pres-
ence of statistical heterogeneity (defined as an I2 statistic
of >25% in a pooled estimate), we will conduct subgroup
analyses and univariate meta-regression (P value <0.10
considered significant given the low power of these tests)
in order to determine the effect of study-level covariates
on the estimates of cumulative incidence, incidence rate,
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of interest will include type of brain injury (isolated TBI
versus poly-trauma); mechanism of TBI (blunt versus
penetrating); severity of TBI (mild TBI (Glasgow Coma
Score ≥13) versus moderate TBI (Glasgow Coma Score
of 9 to 12) versus severe TBI (Glasgow Coma Score ≤8));
severity of injury (major trauma (Injury Severity Score >15)
versus minor trauma (Injury Severity Score ≤15)); ICU
versus non-ICU (studies in which participants are
described as an ICU patient population versus studies in
which participants are patients of a non-ICU hospital
unit); and the percentage of participants that received
mechanical ventilation (<25% versus 25% to 49% versus
50% to 74% versus ≥75%).
Influence and outlier analyses will also be conducted
in order to determine whether certain studies were par-
ticularly influential on the pooled estimates of infection
occurrence [39]. Studies deemed to be particularly influ-
ential on our created random effects models or to be
outliers will be identified and excluded in turn from the
model to determine their effect on our pooled estimates
[39]. Any identified influential studies will then be reported,
as will their effect on the overall pooled estimate. Small
study effects potentially due to publication bias will also be
assessed using the methods suggested by Begg and Egger
[40,41]. Stata Statistical Software version 12.0 (StataCorp
LP, College Station, TX, USA), particularly the metan
and meta commands, will be used for all analyses.
Discussion
This systematic review and meta-analysis will be performed
to critically examine the world’s relevant literature on the
epidemiology of post-TBI infection. Specifically, we aim to
estimate the frequency of occurrence of infection among
adults hospitalized after TBI by synthesizing and comparing
the incidence, prevalence, and occurrence rate of infection
observed across randomized and non-randomized studies.
We will also identify study and population characteristics
associated with infection, define risk groups based on TBI
severity (mild, moderate, severe) and ICU stay, and identify
sources of heterogeneity across these studies. Understand-
ing the rates of infection among patients with TBI could
help target patient subgroups that may benefit from early
infection screening, prevention, and treatment efforts.
Also, quantifying the burden of post-TBI infection will
help guide decision-making for the allocation of scarce
healthcare resources and funding. Results are expected
to be publicly available near the conclusion of 2013.Additional files
Additional file 1: Appendix 1. Proposed MEDLINE search strategy.
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